Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 20;8(5):e1040.
doi: 10.1212/NXI.0000000000001040. Print 2021 Jul.

Serum Contactin-1 in CIDP: A Cross-Sectional Study

Luuk Wieske  1 , Lorena Martín-Aguilar  2 , Janev Fehmi  2 , Cinta Lleixà  2 , Marleen J A Koel-Simmelink  2 , Madhurima Chatterjee  2 , Zoë van Lierop  2 , Joep Killestein  2 , Camiel Verhamme  2 , Luis Querol  2 , Simon Rinaldi  2 , Charlotte E Teunissen  2 , Filip Eftimov  2
Affiliations

Serum Contactin-1 in CIDP: A Cross-Sectional Study

Luuk Wieske et al. Neurol Neuroimmunol Neuroinflamm. .

Abstract

Objective: To investigate whether serum levels of contactin-1, a paranodal protein, correlate with paranodal injury as seen in patients with CIDP with antibodies targeting the paranodal region.

Methods: Serum contactin-1 levels were measured in 187 patients with CIDP and 222 healthy controls. Paranodal antibodies were investigated in all patients.

Results: Serum contactin-1 levels were lower in patients (N = 41) with paranodal antibodies compared with patients (N = 146) without paranodal antibodies (p < 0.01) and showed good discrimination between these groups (area under the curve 0.84; 95% CI: 0.76-0.93).

Conclusions: These findings suggest that serum contactin-1 levels have the potential to serve as a possible diagnostic biomarker of paranodal injury in CIDP.

Classification of evidence: This study provides class II evidence that serum contactin-1 levels can discriminate between patients with CIDP with or without paranodal antibodies with a sensitivity of 71% (95% CI: 56%-85%) and a specificity of 97% (95% CI: 83%-100%).

PubMed Disclaimer

Figures

Figure
Figure. Serum Contactin-1 Levels in Patients With CIDP With or Without Paranodal Antibodies
Serum contactin-1 (sCNTN1) levels in healthy controls (gray) and patients with CIDP (black) categorized according to the presence or absence of the different nodal and paranodal antibodies. The black line indicates the median per group. CNTN1 = contactin-1; Caspr1 = contactin-1–associated protein 1; NF-155 = neurofascin-155; NF186 = neurofascin186.
See this image and copyright information in PMC

References

    1. Faivre-Sarrailh C, Devaux JJ. Neuro-glial interactions at the nodes of Ranvier: implication in health and diseases. Front Cell Neurosci. 2013;7:196. - PMC - PubMed
    1. Bunschoten C, Jacobs BC, Van den Bergh PYK, Cornblath DR, van Doorn PA. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019;18(8):784-794. - PubMed
    1. Durbec P, Gennarini G, Goridis C, Rougon G. A soluble form of the F3 neuronal cell adhesion molecule promotes neurite outgrowth. J Cell Biol. 1992;117(4):877-887. - PMC - PubMed
    1. van Lierop ZY, Wieske L, Koel-Simmelink MJ, et al. . Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis. Mult Scler J. 2021:135245852110100. - PMC - PubMed
    1. Ai N, Liu H, Zhou H, et al. . Cytokines and chemokines expression in serum of patients with neuromyelitis optica. Neuropsychiatr Dis Treat. 2019;15:303-310. - PMC - PubMed

Publication types